Lrig1 Antikörper (C-Term)
(1 reference)-
- Target Alle Lrig1 Antikörper anzeigen
- Lrig1 (Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1))
-
Bindungsspezifität
- AA 801-829, C-Term
-
Reaktivität
- Maus
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser Lrig1 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Aufreinigung
- This antibody is purified through a protein A column, followed by peptide affinity purification.
- Immunogen
- This LRIG1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 801-829 amino acids from the C-terminal region of human LRIG1.
- Klon
- RB40253
- Isotyp
- Ig Fraction
- Top Product
- Discover our top product Lrig1 Primärantikörper
-
anti-Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) (AA 1001-1093) antibody
Lrig1 Reaktivität: Human, Maus, Ratte WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
anti-Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) (AA 35-220) antibodyLrig1 Reaktivität: Human ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) (AA 35-220) antibodyLrig1 Reaktivität: Human WB Wirt: Kaninchen Polyclonal unconjugated
anti-Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) (AA 739-995) antibodyLrig1 Reaktivität: Human WB, IHC, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) (AA 801-829) antibodyLrig1 Reaktivität: Maus WB, ELISA Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
- WB: 1:1000
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Haltbarkeit
- 6 months
-
-
: "Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity." in: Journal of neuro-oncology, Vol. 94, Issue 2, pp. 183-94, (2009) (PubMed).
-
: "Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity." in: Journal of neuro-oncology, Vol. 94, Issue 2, pp. 183-94, (2009) (PubMed).
-
- Target
- Lrig1 (Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1))
- Andere Bezeichnung
- LRIG1 (Lrig1 Produkte)
- Synonyme
- LIG-1 antikoerper, LIG1 antikoerper, D6Bwg0781e antikoerper, Img antikoerper, leucine rich repeats and immunoglobulin like domains 1 antikoerper, leucine-rich repeats and immunoglobulin-like domains 1 antikoerper, LRIG1 antikoerper, Lrig1 antikoerper
- Hintergrund
- LRIG1 act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.
- Molekulargewicht
- 119113
- NCBI Accession
- NP_056356
- UniProt
- Q96JA1
-
